Imhotex is a virtual biopharmaceutical company developing products to treat Crohn’s Disease.
Imhotex was founded in 2020 to bring a single drug candidate into the clinic.
Imhotex is a virtual drug development company, staffed by senior leaders with extensive experience in the discovery and development of innovative pharmaceuticals. Development of its asset is achieved through engagement of a range of carefully selected service providers with specialist expertise in the key areas required for rapid advancement of the product candidate into the clinic.
Imhotex is developing a product candidate for Crohn’s Disease. Crohn’s Disease (CD) and ulcerative colitis (UC), together inflammatory bowel disease (IBD) are chronic relapsing and remitting afflictions that impose a life-long burden on an increasingly large portion of the population. The incidence of CD is approximately 1 in 500 and the annual costs of treating these patients is approximately $20 billion in the USA.
CD is a chronic inflammatory disease that may affect any part of the gastrointestinal tract with patchy, transmural and granulomatous inflammation. Symptoms often include abdominal pain, diarrhoea, fever and weight loss. CD can have systemic manifestations such as inflammation of the eye, arthritis, skin rashes, clubbing of fingers and aphthous ulcers. Bowel obstruction may occur and those with CD are at greater risk of bowel cancer.
Patients are currently treated with anti-inflammatory agents such as steroids, immunosuppressants and biologics like anti-TNFs. Despite this, a significant proportion of patients undergo surgery, after which they are temporarily free of the disease. Approximately 50% of these subjects will relapse with current treatment. Imhotex is developing a treatment that we believe will be superior to existing therapy.
Imhotex
C/O The Cambridge Partnership
Babraham Research Campus,
Babraham Cambridge, UK
CB22 3FH
For all enquiries